[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: Making transformative advances against childhood cancer: A conversation with Dr. Doug Hawkins The FDA has approved sodium thiosulfate
Assorted News from the Last Week: The FDA has approved sodium thiosulfate (Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients
Assorted News from the Last Week: Supporting Children and Families Through a Cancer Diagnosis by Child Life Specialist Nicolle Bengtson. Nearly 20 years since her
Assorted News from the Last Two Weeks: National Cancer Institute’s CCDI Molecular Characterization Initiative adds rare tumors. Study provides first in-depth look at major mix-ups
Children, adolescents, and young adults (AYAs) with newly diagnosed rare tumors are now eligible to enroll in the CCDI Molecular Characterization Initiative. Rare tumors are
Assorted News from the Last Two Weeks: The Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for the treatment of children aged 1 year or
Assorted News from the Last Week: Leukemia and Lymphoma Society’s (LLS) has launched its Dare to Dream Project as an extension of itself Children’s Initiative.
The Molecular Targets Platform is an NCI-supported instance of the Open Targets Platform with a focus on preclinical pediatric oncology data. It is a tool
Assorted News from the Last Two Weeks: The CCDI Molecular Targets Platform is the National Cancer Institute’s instance of the Open Targets Platform, specific to
[vc_row][vc_column][vc_column_text]Update from our colleagues at the Alliance for Childhood Cancer (July 28, 2022): The Senate Appropriations Committee included language to fund the Childhood Cancer STAR
